CN102617500A - 一种新的利奈唑胺中间体、其制备方法和利奈唑胺的新制备方法 - Google Patents
一种新的利奈唑胺中间体、其制备方法和利奈唑胺的新制备方法 Download PDFInfo
- Publication number
- CN102617500A CN102617500A CN2011100611105A CN201110061110A CN102617500A CN 102617500 A CN102617500 A CN 102617500A CN 2011100611105 A CN2011100611105 A CN 2011100611105A CN 201110061110 A CN201110061110 A CN 201110061110A CN 102617500 A CN102617500 A CN 102617500A
- Authority
- CN
- China
- Prior art keywords
- linezolid
- preparation
- ammonia
- fluoro
- tartrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 title claims abstract description 66
- 229960003907 linezolid Drugs 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 54
- 239000000460 chlorine Chemical group 0.000 claims abstract description 14
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 7
- 239000011737 fluorine Substances 0.000 claims abstract description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 3
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 3
- 229910052740 iodine Chemical group 0.000 claims abstract description 3
- 239000011630 iodine Chemical group 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 43
- -1 (3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl) methylol Chemical class 0.000 claims description 36
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 28
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 238000005406 washing Methods 0.000 claims description 18
- 239000012141 concentrate Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 150000001263 acyl chlorides Chemical class 0.000 claims description 14
- 229910021529 ammonia Inorganic materials 0.000 claims description 14
- 239000010977 jade Substances 0.000 claims description 12
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 claims description 10
- 239000000543 intermediate Substances 0.000 claims description 9
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 7
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 claims description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- KMPWYEUPVWOPIM-LSOMNZGLSA-N cinchonine Chemical class C1=CC=C2C([C@@H]([C@H]3N4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-LSOMNZGLSA-N 0.000 claims description 4
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- LSPHULWDVZXLIL-LDWIPMOCSA-N (?)-Camphoric acid Chemical compound CC1(C)[C@@H](C(O)=O)CC[C@@]1(C)C(O)=O LSPHULWDVZXLIL-LDWIPMOCSA-N 0.000 claims description 3
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims description 3
- 240000008042 Zea mays Species 0.000 claims description 3
- 235000007244 Zea mays Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 150000003892 tartrate salts Chemical class 0.000 claims description 3
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000006103 sulfonylation Effects 0.000 claims description 2
- 238000005694 sulfonylation reaction Methods 0.000 claims description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000012467 final product Substances 0.000 abstract description 2
- 239000013067 intermediate product Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 56
- 239000000243 solution Substances 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000012544 monitoring process Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000003756 stirring Methods 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000012043 crude product Substances 0.000 description 10
- 230000003287 optical effect Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 241000237502 Ostreidae Species 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 235000004338 Syringa vulgaris Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 235000020636 oyster Nutrition 0.000 description 4
- 238000007670 refining Methods 0.000 description 4
- VIKSTSDUVSJVFX-UHFFFAOYSA-N O=C(N(C(OCC1=CC=CC=C1)=O)C(C=C1)=CC(F)=C1N1CCOCC1)OCC1=CC=CC=C1 Chemical compound O=C(N(C(OCC1=CC=CC=C1)=O)C(C=C1)=CC(F)=C1N1CCOCC1)OCC1=CC=CC=C1 VIKSTSDUVSJVFX-UHFFFAOYSA-N 0.000 description 3
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 2
- JIFAWAXKXDTUHW-UHFFFAOYSA-N 2-fluorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1F JIFAWAXKXDTUHW-UHFFFAOYSA-N 0.000 description 2
- FQGIBHQUVCGEAC-UHFFFAOYSA-N 3-Fluoro-4-morpholinoaniline Chemical compound FC1=CC(N)=CC=C1N1CCOCC1 FQGIBHQUVCGEAC-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical class NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- 0 *c(cc1)ccc1S(OC[C@@](CN1c(cc2)cc(F)c2N2CCOCC2)OC1=O)(=O)=O Chemical compound *c(cc1)ccc1S(OC[C@@](CN1c(cc2)cc(F)c2N2CCOCC2)OC1=O)(=O)=O 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JUSXLWAFYVKNLT-UHFFFAOYSA-N 2-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1Br JUSXLWAFYVKNLT-UHFFFAOYSA-N 0.000 description 1
- MWWNNNAOGWPTQY-UHFFFAOYSA-N 3-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(S(Cl)(=O)=O)=C1 MWWNNNAOGWPTQY-UHFFFAOYSA-N 0.000 description 1
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000544061 Cuculus canorus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000005642 Gabriel synthesis reaction Methods 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- YLNSNVGRSIOCEU-ZCFIWIBFSA-N [(2r)-oxiran-2-yl]methyl butanoate Chemical compound CCCC(=O)OC[C@H]1CO1 YLNSNVGRSIOCEU-ZCFIWIBFSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005915 ammonolysis reaction Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- YBIUHXGZDJCHIF-UHFFFAOYSA-N azane;methanol Chemical compound N.N.OC YBIUHXGZDJCHIF-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- ASCHBOWFKWDVGW-UHFFFAOYSA-N fluorobenzene;sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O.FC1=CC=CC=C1 ASCHBOWFKWDVGW-UHFFFAOYSA-N 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- HGALOWHSZJDJIR-UHFFFAOYSA-N iodobenzene;sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O.IC1=CC=CC=C1 HGALOWHSZJDJIR-UHFFFAOYSA-N 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- RMNJNEUWTBBZPT-UHFFFAOYSA-N methyl 4-nitrobenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 RMNJNEUWTBBZPT-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- YLNSNVGRSIOCEU-UHFFFAOYSA-N oxiran-2-ylmethyl butanoate Chemical compound CCCC(=O)OCC1CO1 YLNSNVGRSIOCEU-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110061110.5A CN102617500B (zh) | 2011-01-31 | 2011-03-09 | 一种利奈唑胺中间体、其制备方法和利奈唑胺的制备方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110036738 | 2011-01-31 | ||
CN201110036738.X | 2011-01-31 | ||
CN201110036738X | 2011-01-31 | ||
CN201110061110.5A CN102617500B (zh) | 2011-01-31 | 2011-03-09 | 一种利奈唑胺中间体、其制备方法和利奈唑胺的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102617500A true CN102617500A (zh) | 2012-08-01 |
CN102617500B CN102617500B (zh) | 2016-07-13 |
Family
ID=46557762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110061110.5A Withdrawn - After Issue CN102617500B (zh) | 2011-01-31 | 2011-03-09 | 一种利奈唑胺中间体、其制备方法和利奈唑胺的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102617500B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113045509A (zh) * | 2021-06-01 | 2021-06-29 | 上海翰森生物医药科技有限公司 | 利奈唑胺的工业生产方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1130379A (zh) * | 1993-09-09 | 1996-09-04 | 厄普约翰公司 | 取代的噁嗪和噻嗪噁唑烷酮抗微生物剂 |
US5929083A (en) * | 1997-05-24 | 1999-07-27 | Cheil Jedang Corporation | Oxazolidinone derivatives and a method for the preparation thereof and an antibacterial composition containing the same |
CN1835909A (zh) * | 2003-06-13 | 2006-09-20 | 艾夫西亚药品有限公司 | 芳胺的制备方法 |
WO2010084514A2 (en) * | 2009-01-02 | 2010-07-29 | Neuland Laboratories Ltd. | A process for the preparation of (5s)-(n)-[[3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide |
-
2011
- 2011-03-09 CN CN201110061110.5A patent/CN102617500B/zh not_active Withdrawn - After Issue
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1130379A (zh) * | 1993-09-09 | 1996-09-04 | 厄普约翰公司 | 取代的噁嗪和噻嗪噁唑烷酮抗微生物剂 |
US5929083A (en) * | 1997-05-24 | 1999-07-27 | Cheil Jedang Corporation | Oxazolidinone derivatives and a method for the preparation thereof and an antibacterial composition containing the same |
CN1835909A (zh) * | 2003-06-13 | 2006-09-20 | 艾夫西亚药品有限公司 | 芳胺的制备方法 |
WO2010084514A2 (en) * | 2009-01-02 | 2010-07-29 | Neuland Laboratories Ltd. | A process for the preparation of (5s)-(n)-[[3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide |
Non-Patent Citations (2)
Title |
---|
GUANGYU XU,等: "A Convenient Synthesis of Oxazolidinone Derivatives Linezolid and Eperezolid from (S)-Glyceraldehyde Acetonide", 《HETEROATOM CHEMISTRY》 * |
陈炜,等: "利奈唑胺合成路线图解", 《中国医药工业杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113045509A (zh) * | 2021-06-01 | 2021-06-29 | 上海翰森生物医药科技有限公司 | 利奈唑胺的工业生产方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102617500B (zh) | 2016-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021204209B2 (en) | Processes and intermediates in the preparation of C5aR antagonists | |
CN102786516B (zh) | 一种利伐沙班的合成方法 | |
CA2885471C (en) | Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | |
JP4852419B2 (ja) | 4−(4−アミノフェニル)−3−モルホリノンの製造方法 | |
JP2016500106A5 (zh) | ||
WO2005033064A1 (en) | Process of preparing o-carbamoyl compounds in the presence of active amine group | |
JP2009522210A (ja) | 2,2’,6,6’−テトラオキサゾリンビフェニル配位子およびその調製方法 | |
TW201343642A (zh) | 製備利伐沙班(rivaroxaban)之方法 | |
CN102617500A (zh) | 一种新的利奈唑胺中间体、其制备方法和利奈唑胺的新制备方法 | |
CN103130700B (zh) | 一种阿折地平中间体的制备方法 | |
CZ20003457A3 (cs) | Způsob výroby inhibitorů HIV proteázy | |
KR101327866B1 (ko) | 미티글리나이드 칼슘염의 개선된 제조방법 | |
WO2014009964A1 (en) | Process for enantiomeric enrichment of 2 ', 6 ' - pipecoloxylidide | |
KR101520187B1 (ko) | 이오프로마이드의 중간체의 제조방법 | |
CN104136422B (zh) | 化合物、化合物的制造方法、以及化合物的精制方法 | |
CN103012264B (zh) | 3‑取代氨基‑六氢‑1h‑氮杂环庚烷的拆分方法 | |
CN105330612B (zh) | 2‑(5‑氨基‑1,2,4‑噻二唑‑3‑基)‑2‑甲氧亚氨基乙酸的合成工艺 | |
CN108250140B (zh) | 一种马来酸茚达特罗的制备方法 | |
CN111004235A (zh) | 一种ATX抑制剂Ziritaxestat的合成方法 | |
CN104245692B (zh) | 用于制备高纯度methiozolin的工业方法 | |
CN105924400A (zh) | 阿齐沙坦杂质a和b的制备方法 | |
JP6948693B2 (ja) | アジルサルタン合成中間体の製造方法 | |
CN108602808A (zh) | 合成奈比洛尔中间体的方法 | |
CN103626712B (zh) | 一种用于制备利奈唑胺的中间体及其制备方法 | |
CN112521330A (zh) | 一种新的匹莫范色林的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG SALUBRIS PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Effective date: 20150630 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150630 Address after: 253000 Linyi Economic Development Zone, Shandong, Dezhou Applicant after: Shandong Xinlitai Pharmaceutical Co., Ltd. Address before: Shenzhen City, Guangdong Province, 518040 Shennan Road No. 6009 Che Kung Temple Green Plaza building 37 layer Applicant before: Shenzhen Salubris Pharmaceuticals Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
AV01 | Patent right actively abandoned | ||
AV01 | Patent right actively abandoned |
Granted publication date: 20160713 Effective date of abandoning: 20210317 |
|
AV01 | Patent right actively abandoned |
Granted publication date: 20160713 Effective date of abandoning: 20210317 |
|
AV01 | Patent right actively abandoned |